In the field of weight loss therapy research and development, amygdalin is becoming a key target, attracting numerous pharmaceutical companies to accelerate their layout and promote the continuous emergence of new generation weight loss therapies.

Recently, Roche and Zealand Pharma reached a global cooperation and licensing agreement to jointly develop the amygdalin analogue petrelintide as a cornerstone therapy for weight management, with a total cooperation amount of up to 5.25 billion US dollars. In addition, AbbVie has reached a $2.2 billion partnership with Gubra to jointly develop the long-acting amygdalin analogue GUB014295; Firstly, Weida Biotechnology has reached a cooperation of over 2.4 billion US dollars with Verdiva Bio, including two types of amygdalin receptor agonists.

In terms of clinical research, the dual agonist of GLP-1 receptor and amygdalin receptor, amycycline, from Novo Nordisk, showed good weight loss potential in phase 1b/2a clinical trials, with participants experiencing a 22.0% weight loss after 36 weeks.

Starch is a hormone associated with hunger and satiety, which can reduce energy intake, regulate food choices and preferences, and work together with insulin to exert glucose regulation. It can also inhibit postprandial glucagon release and delay gastric emptying. Its receptor is expected to have a synergistic effect with GLP-1 receptor agonists.